WO2021246373A1 - Dispersion - Google Patents

Dispersion Download PDF

Info

Publication number
WO2021246373A1
WO2021246373A1 PCT/JP2021/020706 JP2021020706W WO2021246373A1 WO 2021246373 A1 WO2021246373 A1 WO 2021246373A1 JP 2021020706 W JP2021020706 W JP 2021020706W WO 2021246373 A1 WO2021246373 A1 WO 2021246373A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxyapatite
water
dispersion liquid
powder
dispersion
Prior art date
Application number
PCT/JP2021/020706
Other languages
French (fr)
Japanese (ja)
Inventor
忠 川本
敦史 内山
Original Assignee
株式会社トレスバイオ研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社トレスバイオ研究所 filed Critical 株式会社トレスバイオ研究所
Priority to JP2022528826A priority Critical patent/JPWO2021246373A1/ja
Publication of WO2021246373A1 publication Critical patent/WO2021246373A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D39/00Filtering material for liquid or gaseous fluids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/04Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26Synthetic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/32Phosphates of magnesium, calcium, strontium, or barium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Definitions

  • the present invention relates to a dispersion liquid in which a water-insoluble powder such as hydroxyapatite is dispersed.
  • Hydroxyapatite is a hydroxide of calcium and phosphoric acid, and is used as a biomaterial such as artificial bone and an oral composition material because of its high biocompatibility. In recent years, hydroxyapatite powder has been excellently adsorbed. Research and development are underway for various uses for adsorbing bacteria, proteins, lipids, etc. by utilizing their properties.
  • the present invention advantageously solves the above-mentioned problems, and an object of the present invention is to provide a dispersion liquid in which a water-insoluble powder is stably dispersed, which can be used for coating or spraying hydroxyapatite or other water-insoluble powder. And.
  • the present inventors can solve the above-mentioned problems by dispersing hydroxyapatite and a cellulose derivative, and by dispersing not only hydroxyapatite but also other water-insoluble powders with a cellulose derivative. We have found that the above problems can be solved, and have completed the present invention.
  • the present invention is as follows [1] to [12].
  • [1] A dispersion liquid of a water-insoluble powder, which comprises a cellulose derivative.
  • [2] The dispersion liquid of [1], wherein the water-insoluble powder is hydroxyapatite.
  • [3] The dispersion liquid of [1] or [2], which does not substantially precipitate a water-insoluble powder when centrifuged at 3600 rpm for 10 minutes.
  • [5] The dispersion liquid according to any one of [1] to [4], wherein the solvent is water.
  • the dispersion liquid according to any one of [1] to [7] which contains an antibacterial agent.
  • a dispersion liquid of a water-insoluble powder which comprises a step of mixing a water-insoluble powder, a cellulose derivative and a polar solvent to produce a paste composition, and a step of dispersing the paste composition in a polar solvent. Production method.
  • a filter comprising a hydroxyapatite and a cellulose derivative.
  • a water-insoluble powder such as hydroxyapatite can be stably and uniformly dispersed in a liquid.
  • the dispersion liquid of the present invention contains a water-insoluble powder such as hydroxyapatite powder and a cellulose derivative.
  • Hydroxyapatite powder has been attempted to be applied to various applications that require adsorptivity, but even if hydroxyapatite powder was added to water and stirred, it was not sufficiently dispersed. On the other hand, by dispersing the hydroxyapatite powder and the cellulose derivative, a stable dispersion of hydroxyapatite can be obtained.
  • the water-insoluble powder will be described by taking hydroxyapatite as an example.
  • the lower limit of hydroxyapatite is not particularly defined in the dispersion liquid of the present invention, and may contain, for example, 0.1% by mass or more, preferably 2% by mass or more, more preferably 3% by mass or more, and more preferably. Can be contained in an amount of 5% by mass or more, more preferably 10% by mass or more. There has never been a technique for uniformly dispersing such high-concentration hydroxyapatite in water. Further, it has been confirmed that the dispersion liquid of the present invention can contain 40% by mass or 45% by mass without any particular upper limit of hydroxyapatite. Preferably, hydroxyapatite can be contained in an amount of 20% by mass or less.
  • the dispersion liquid of the present invention is one in which hydroxyapatite is stably dispersed, and precipitation is unlikely to occur even if it is allowed to stand. Whether or not precipitation is unlikely to occur can be quickly confirmed by centrifuging.
  • the dispersion of the present invention has substantially no precipitation of hydroxyapatite after centrifugation at 3600 rpm for 10 minutes at room temperature, and substantially no precipitation of hydroxyapatite after being allowed to stand at room temperature for 12 hours. Those that do not occur are preferable.
  • the fact that hydroxyapatite precipitates do not substantially occur means that a white precipitate cannot be clearly confirmed by visual inspection.
  • the dispersion liquid in which hydroxyapatite is uniformly dispersed can adhere hydroxyapatite to any object, for example, non-woven fabric, filter, gauze, mask, wall, etc. by application.
  • the coating method is not particularly limited, and examples thereof include spray coating, dipping, potting, roller coating, spin coating and the like. Since these coating methods can be applied uniformly, are simple and suitable for mass production, products to which hydroxyapatite is attached can be mass-produced at low cost.
  • the mask and filter of the present invention can be expected to have the effect of reducing the amount of hydroxyapatite powder falling off.
  • hydroxyapatite powder has adsorptive properties, for example, by applying an aqueous dispersion of hydroxyapatite to a non-woven fabric or a mask and adhering hydroxyapatite to these objects, pollen, PM2.5, viruses, etc. are adsorbed. Can be expected. Further, according to the dispersion liquid of the present invention, not only hydroxyapatite powder but also at least one powder selected from carbon powder, zinc powder and food material powder can be stably dispersed.
  • the components of the dispersion liquid of the present invention will be described more specifically.
  • the water-insoluble powder refers to a powder that is insoluble in water, and examples of the powder that can be stably dispersed by the technique of the present invention include hydroxyapatite, carbon powder, zinc powder, and food powder.
  • hydroxyapatite commercially available hydroxyapatite can be used.
  • Commercially available hydroxyapatite includes those derived from minerals and those derived from living organisms, and any hydroxyapatite derived from minerals or living organisms can be used, but hydroxyapatite derived from living organisms is preferable.
  • Organism-derived hydroxyapatite is hydroxyapatite obtained by using biological components (bone, coral, shell, eggshell, etc.) as a calcium source for obtaining hydroxyapatite.
  • a phosphoric acid solution is added to a calcium oxide solution (suspension) or a calcium hydroxide solution (suspension), or a calcium oxide solution (suspension) or calcium hydroxide is added to the phosphoric acid solution. It can be obtained by adding a solution (suspension).
  • Hydroxyapatite derived from living organisms is, for example, calcined biological materials containing calcium such as bones, coral, shells, and eggshells to obtain calcium oxide or calcium hydroxide, which is used as an aqueous solution or a suspension. , Hydroxyapatite obtained by the addition of a phosphoric acid solution. Further, in the hydroxyapatite derived from living organisms, the crystallite size of the peak in which 2 ⁇ appears at 31.500 to 32.500 ° in X-ray structural analysis is 10 to 200 ⁇ , preferably 30 to 150 ⁇ , more preferably 50. Some are hydroxyapatite up to 120 ⁇ (hereinafter, also referred to as "specific hydroxyapatite" for the sake of explanation).
  • the crystallinity size represents the size of crystal grains and is a numerical value that serves as a guide for expressing crystallinity. The larger the value of the crystallinity size, the higher the crystallinity of the substance to be measured.
  • Hydroxyapatite having a crystallite size in the above range is only uncrystallized (amorphous) hydroxyapatite or a mixture of amorphous hydroxyapatite and low degree of crystallization (low crystal type) hydroxyapatite.
  • the "amorphous hydroxyapatite" in the present invention means a substance for which a chart as shown in FIG. 3 can be obtained by X-ray analysis.
  • the "low crystalline hydroxyapatite" in the present invention means that the chart obtained by X-ray analysis has a peak as compared with the chart obtained by X-ray analysis of crystalline hydroxyapatite (see, for example, the chart in FIG. 2). It is a substance with a relatively low degree of separation.
  • the crystallite size can be measured by, for example, an X-ray analyzer model number: RINT2200V / PC manufactured by Rigaku Co., Ltd.
  • the hydroxyapatite may contain hydroxyapatite or the like other than the above-mentioned specific hydroxyapatite.
  • Hydroxyapatite derived from eggshell has the trade name Bioapatite (trademark) of Bioapatite Co., Ltd. At present, the only specific hydroxyapatite available on the market is bioapatite, so the specific hydroxyapatite available on the market is presumed to be eggshell-derived apatite.
  • the average particle size of the hydroxyapatite used in the present invention is not particularly limited, but the average particle size is preferably 1 to 30 ⁇ m, more preferably 1 to 20 ⁇ m, and further preferably 1 to 10 ⁇ m.
  • the average particle size can be measured by a laser light scattering diffraction method.
  • the cellulose derivative of the present invention is cellulose or a compound in which cellulose is substituted or chemically modified, or a salt thereof.
  • the degree of substitution of cellulose is not particularly limited.
  • examples of the cellulose derivative include cellulose, methyl cellulose, carboxymethyl cellulose and sodium carboxymethyl cellulose, and methyl cellulose or a salt thereof or carboxymethyl cellulose or a salt thereof (for example, sodium carboxymethyl cellulose) is preferable, and methyl cellulose is more preferable.
  • Commercially available sodium carboxymethyl cellulose can be used as a thickener or the like. There are food additive grade and industrial grade, but any of them can be used depending on the use of the dispersion.
  • the particle size of the powder is not particularly limited, and a commercially available cellulose derivative can be used as it is.
  • the content of the cellulose derivative such as methyl cellulose and sodium carboxymethyl cellulose is 2% by mass or less, preferably 0.1 to 2% by mass in the dispersion liquid containing water. It is difficult to dissolve a content of more than 2% by mass in water.
  • the lower limit is not particularly limited, but if the content is low, the effect of dispersing the hydroxyapatite powder in water is reduced.
  • the polar solvent is a solvent containing a hydrogen atom bonded to oxygen (hydroxy group), nitrogen (amine) or the like, and is used when producing a paste composition containing hydroxyapatite and a cellulose derivative. It can also be used as a solvent for hydroxyapatite dispersion.
  • the polar solvent include water, glycerin, polyethylene glycol, glycerol, alcohol (methanol, ethanol, butanol, propanol), formic acid, acetic acid or a mixture thereof.
  • a buffer such as PBS or PBST or an aqueous solution containing a component such as EDTA, DTT or mercaptoethanol can be used as the polar solvent.
  • the solvent of the hydroxyapatite dispersion and the polar solvent in the paste composition do not have to be the same.
  • Water is preferable as the solvent for the hydroxyapatite dispersion.
  • As the polar solvent of the paste composition glycerin and polyethylene glycol are preferable.
  • a commercially available enzyme solution may be used as it is, and a polar solvent may not be added separately. This is because a commercially available enzyme is stored in a polar solvent, and a paste composition can be produced by using this polar solvent.
  • the preferable mixing ratio of the polar solvent in the paste composition is 100 to 200 g of the organic liquid with respect to 10 g of hydroxyapatite.
  • the dispersion of the present invention can contain functional components such as antibacterial components in addition to hydroxyapatite and cellulose derivatives.
  • an antibacterial effect can be exerted by the action of the antibacterial component when the dispersion liquid is attached to a mask or a non-woven fabric.
  • the hydroxyapatite dispersion of the present invention contains an antibacterial component, it can be expected to have an effect equal to or higher than that of rubbing alcohol. This is because the disinfecting alcohol is volatile, so that the disinfecting effect is temporary, but the dispersion of the present invention can be expected to have a long-lasting antibacterial effect.
  • antibacterial components examples include copper, silver, cetylpyridinium chloride (CPC), isopropylmethylphenol (IPMP), lauroylsarcosine sodium (LSS), chlorhexidine hydrochloride (CHX), triclosan (TC), etc. contained in commercially available dentifrices. be. These antibacterial components do not reduce their antibacterial activity even when added to the dispersion of the present invention.
  • a polar solvent such as water is added to the obtained paste composition to obtain an aqueous dispersion having a predetermined concentration of hydroxyapatite powder.
  • the same polar solvent as the polar solvent used to obtain the paste composition.
  • high-purity water for example, reverse osmosis membrane water can be used, but tap water can also be used depending on the application.
  • the hydroxyapatite powder When the antibacterial component is added, the hydroxyapatite powder may be added to the aqueous dispersion having a predetermined concentration, or the antibacterial component may be added at the time of the previous step. According to the production method of the present invention, a dispersion containing a high concentration of hydroxyapatite can be produced with high efficiency and low cost.
  • the dispersion liquid of the present invention can be applied to non-woven fabrics, gauze, masks, filters, walls and the like.
  • the coating method is not particularly limited, and examples thereof include spray coating, dipping, potting, roller coating, spin coating and the like.
  • Nonwoven fabric, gauze, etc. coated with a dispersion liquid can be processed into a mask, and can also be used as a filter for an air conditioner or the like.
  • the adsorption effect of hydroxyapatite can be expected to adsorb pollen, PM2.5, viruses and the like.
  • the application of the dispersion liquid of the present invention is not limited to the above-mentioned masks and filters, but can be applied to a wide range of applications such as air purification, and has great industrial applicability.
  • hydroxyapatite (trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.) commercially available as hydroxyapatite, and bioapatite (hereinafter, "egguapatite"), which is a hydroxyapatite derived from eggshell as the specific hydroxyapatite described above. I prepared.).
  • egguapatite bioapatite
  • sodium carboxymethyl cellulose of Wako Pure Chemical Industries, Ltd. was prepared.
  • glycerin was prepared as a polar solvent.
  • Example 10 g of hydroxyapatite and 0.1 g of sodium carboxymethyl cellulose were mixed. This mixture was added to 10 g of glycerin and stirred to obtain a paste composition. 50 cm 3 of water was added to the obtained paste composition and stirred to obtain an aqueous dispersion (hereinafter, the hydroxyapatite dispersion is referred to as "Example").
  • FIGS. 4 and 5 The photographs are shown in FIGS. 4 and 5.
  • the right side of FIGS. 4 and 5 is an example, and hydroxyapatite is an example of hydroxyapatite derived from eggshell, that is, the trade name bioapatite of Bioapatite Co., Ltd., and the left side of FIGS. 4 and 5 is a comparative example.
  • FIG. 4 is a photograph immediately after preparing the dispersion
  • FIG. 5 is a photograph after allowing it to stand at room temperature. As is clear from FIGS.
  • FIGS. 6 and 7 are photographs before centrifugation and FIG. 7 is a photograph after centrifugation. Further, the right side of FIGS. 6 and 7 is an example. As is clear from FIGS. 6 and 7, no precipitation is substantially formed in the examples even after centrifugation. Although not shown in FIGS.
  • hydroxyapatite is commercially available hydroxyapatite, that is, trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.
  • hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.
  • hydroxyapatite aqueous dispersion and egguapatite aqueous dispersion to which cetylpyridinium chloride (CPC) was added as an antibacterial component were left for 10 days, hydroxyapatite precipitation did not occur in any of them. rice field. Further, when observed after being subjected to a centrifuge at 3600 rpm, no precipitation of hydroxyapatite occurred.
  • CPC cetylpyridinium chloride
  • FIGS. 4 and 5 The left side of FIGS. 4 and 5 is a comparative example. As is clear from FIGS. 4 and 5, precipitation occurs in the comparative example. Further, photographs of a comparative example when subjected to a centrifuge are shown in FIGS. 6 and 7. The left side of FIGS. 6 and 7 is an example. As is clear from FIGS. 6 and 7, precipitation occurs in the comparative example after being centrifuged. Further, when 50 cm 3 of water was added to 10 g of egguapatite and stirred, hydroxyapatite was precipitated immediately after the stirring was completed.
  • hydroxyapatite (trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.) was prepared as hydroxyapatite.
  • commercially available methyl cellulose (trade name Metrose manufactured by Shinetsu Cellulose Co., Ltd.) was prepared.
  • glycerin was prepared as a polar solvent.
  • hydroxyapatite (trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.) was prepared as hydroxyapatite.
  • commercially available methyl cellulose (trade name Metrose manufactured by Shinetsu Cellulose Co., Ltd.) was prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A dispersion is provided in which a water-insoluble powder, e.g., hydroxyapatite, is stably dispersed. The dispersion of a water-insoluble powder is characterized by containing a cellulose derivative.

Description

分散液Dispersion
 本発明は、ハイドロキシアパタイトなどの水不溶粉末を分散させた分散液に関する。 The present invention relates to a dispersion liquid in which a water-insoluble powder such as hydroxyapatite is dispersed.
 ハイドロキシアパタイトは、カルシウムとリン酸との水酸化物であり、生体親和性が高いため人工骨等の生体材料や口腔用組成物材料として用いられている他、近年ではハイドロキシアパタイト粉末が優れた吸着性を有することを利用して、細菌や蛋白質や脂質等を吸着する種々の用途について研究、開発が進められている。 Hydroxyapatite is a hydroxide of calcium and phosphoric acid, and is used as a biomaterial such as artificial bone and an oral composition material because of its high biocompatibility. In recent years, hydroxyapatite powder has been excellently adsorbed. Research and development are underway for various uses for adsorbing bacteria, proteins, lipids, etc. by utilizing their properties.
 しかしながら、ハイドロキシアパタイト粉末などの水に不溶性の粉末は、液体への分散性が悪く、分散させようとすると、沈殿やダマが生じてしまい、分散液を用いた散布、塗布が困難であった。例えば、マスクやエアコンフィルタのような吸着の用途に用いる際に、ハイドロキシアパタイト粉末を塗布することが難しかった。
 本発明は上記の問題を有利に解決するものであり、ハイドロキシアパタイトその他の水不溶粉末の塗布や散布に用いることができる、水不溶粉末を安定的に分散させた分散液を提供することを目的とする。
However, water-insoluble powders such as hydroxyapatite powder have poor dispersibility in liquids, and when they are attempted to be dispersed, precipitation and lumps occur, making it difficult to spray and apply using the dispersion liquid. For example, it has been difficult to apply hydroxyapatite powder when used for adsorption applications such as masks and air conditioner filters.
The present invention advantageously solves the above-mentioned problems, and an object of the present invention is to provide a dispersion liquid in which a water-insoluble powder is stably dispersed, which can be used for coating or spraying hydroxyapatite or other water-insoluble powder. And.
 本発明者らは、鋭意検討した結果、ハイドロキシアパタイトと、セルロース誘導体とを分散させることにより、上記課題を解決しうること、ハイドロキシアパタイトに限られず他の水不溶粉末もセルロース誘導体と分散させることにより上記課題を解決しうることを見いだし、本発明を完成するに至った。 As a result of diligent studies, the present inventors can solve the above-mentioned problems by dispersing hydroxyapatite and a cellulose derivative, and by dispersing not only hydroxyapatite but also other water-insoluble powders with a cellulose derivative. We have found that the above problems can be solved, and have completed the present invention.
 本発明は、以下の[1]~[12]のとおりである。
[1]セルロース誘導体を含むことを特徴とする水不溶粉末の分散液。
[2]前記水不溶粉末がハイドロキシアパタイトである[1]の分散液。
[3]3600rpmで10分間遠心したときに、水不溶粉末の沈殿が実質的に生じない[1]または[2]の分散液。
[4]前記セルロース誘導体が、メチルセルロース若しくはその塩又はカルボキシメチルセルロース若しくはその塩である[1]~[3]のいずれかの分散液。
[5]溶媒が水である[1]~[4]のいずれかの分散液。
[6]水不溶粉末を、0.1質量%以上含有する[1]~[5]のいずれかの分散液。
[7]さらに、酵素を含有する[1]~[6]のいずれかの分散液。
[8]さらに、抗菌剤を含有する[1]~[7]のいずれかの分散液。
[9]水不溶粉末、セルロース誘導体及び極性溶媒を含むペースト組成物。
[10]水不溶粉末、セルロース誘導体及び極性溶媒を混合してペースト組成物を製造する工程、及び前記ペースト組成物を極性溶媒に分散させる工程を含むことを特徴とする水不溶粉末の分散液の製造方法。
[11]ハイドロキシアパタイト及びセルロース誘導体を担持することを特徴とするフィルタ。
[12]ハイドロキシアパタイト及びセルロース誘導体を担持することを特徴とするマスク。
The present invention is as follows [1] to [12].
[1] A dispersion liquid of a water-insoluble powder, which comprises a cellulose derivative.
[2] The dispersion liquid of [1], wherein the water-insoluble powder is hydroxyapatite.
[3] The dispersion liquid of [1] or [2], which does not substantially precipitate a water-insoluble powder when centrifuged at 3600 rpm for 10 minutes.
[4] The dispersion liquid according to any one of [1] to [3], wherein the cellulose derivative is methyl cellulose or a salt thereof or carboxymethyl cellulose or a salt thereof.
[5] The dispersion liquid according to any one of [1] to [4], wherein the solvent is water.
[6] The dispersion liquid according to any one of [1] to [5], which contains 0.1% by mass or more of a water-insoluble powder.
[7] Further, the dispersion liquid according to any one of [1] to [6] containing an enzyme.
[8] Further, the dispersion liquid according to any one of [1] to [7], which contains an antibacterial agent.
[9] A paste composition containing a water-insoluble powder, a cellulose derivative and a polar solvent.
[10] A dispersion liquid of a water-insoluble powder, which comprises a step of mixing a water-insoluble powder, a cellulose derivative and a polar solvent to produce a paste composition, and a step of dispersing the paste composition in a polar solvent. Production method.
[11] A filter comprising a hydroxyapatite and a cellulose derivative.
[12] A mask characterized by carrying hydroxyapatite and a cellulose derivative.
 本発明によればハイドロキシアパタイトのような水不溶粉末を液体に安定的に均一分散させることができる。 According to the present invention, a water-insoluble powder such as hydroxyapatite can be stably and uniformly dispersed in a liquid.
特定ハイドロキシアパタイトのX線回折の一例の結果を表したグラフ図である。It is a graph which showed the result of an example of the X-ray diffraction of a specific hydroxyapatite. 結晶型ハイドロキシアパタイトのX線回折の結果を表したグラフ図である。It is a graph which showed the result of the X-ray diffraction of the crystalline hydroxyapatite. 非結晶型ハイドロキシアパタイトのX線回折の結果を表したグラフ図である。It is a graph which showed the result of the X-ray diffraction of the amorphous hydroxyapatite. 調製直後の、実施例、比較例それぞれの分散液の写真である。It is a photograph of each dispersion liquid of Example and Comparative Example immediately after preparation. 12時間静置後の、実施例、比較例それぞれの分散液の写真である。It is a photograph of each dispersion liquid of Example and Comparative Example after standing for 12 hours. 遠心分離機にかける前の実施例、比較例それぞれの分散液の写真である。It is a photograph of each dispersion liquid of an Example and a comparative example before centrifuging. 遠心分離機にかけた後の実施例、比較例それぞれの分散液の写真である。It is a photograph of each dispersion liquid of an Example and a comparative example after being subjected to a centrifuge. 遠心分離機にかけた後の実施例の分散液の写真である。It is a photograph of the dispersion liquid of the example after centrifuging.
 本発明の分散液、その製造方法、ペースト組成物、分散液を用いたフィルタ及びマスクを、より具体的に説明する。本発明の分散液は、ハイドロキシアパタイト粉末などの水不溶粉末と、セルロース誘導体とを含む。 The dispersion liquid of the present invention, a method for producing the same, a paste composition, a filter and a mask using the dispersion liquid will be described more specifically. The dispersion liquid of the present invention contains a water-insoluble powder such as hydroxyapatite powder and a cellulose derivative.
 ハイドロキシアパタイト粉末は、吸着性が求められる各種用途への適用が試みられているが、水中にハイドロキシアパタイト粉末を添加して攪拌しても十分に分散しなかった。これに対して、ハイドロキシアパタイト粉末とセルロース誘導体とを分散させることで、ハイドロキシアパタイトの安定な分散液を得ることができる。以下、特に断りがない限り、水不溶粉末については、ハイドロキシアパタイトを例にして説明する。 Hydroxyapatite powder has been attempted to be applied to various applications that require adsorptivity, but even if hydroxyapatite powder was added to water and stirred, it was not sufficiently dispersed. On the other hand, by dispersing the hydroxyapatite powder and the cellulose derivative, a stable dispersion of hydroxyapatite can be obtained. Hereinafter, unless otherwise specified, the water-insoluble powder will be described by taking hydroxyapatite as an example.
 本発明の分散液は、ハイドロキシアパタイトの下限値は特に定めることはなく、例えば0.1質量%以上を含むことができるが、好ましくは2質量%以上、より好ましくは3質量%以上、もっと好ましくは5質量%以上、さらに好ましくは10質量%以上、含むことができる。このような高濃度のハイドロキシアパタイトを、水中に均一に分散させる技術は、これまでになかった。また、本発明の分散液は、ハイドロキシアパタイトの上限値は特に定められず、40質量%や45質量%で含むことができることが確認されている。好ましくは、ハイドロキシアパタイトを20質量%以下含むことができる。本発明の分散液は、ハイドロキシアパタイトを安定的に分散させたものであり、静置しても沈殿が生じにくい。沈殿が生じにくいかどうかは、遠心分離にかけることで素早く確認することができる。例えば、本発明の分散液は、室温下、3600rpmで10分間遠心分離した後に、ハイドロキシアパタイトの沈殿が実質的に生じないもの、また、室温下、12時間静置した後にハイドロキシアパタイトの沈殿が実質的に生じないものが好ましい。ここで、ハイドロキシアパタイトの沈殿が実質的に生じないとは、目視した際に白色の沈殿物が明らかに確認できないことをいう。 The lower limit of hydroxyapatite is not particularly defined in the dispersion liquid of the present invention, and may contain, for example, 0.1% by mass or more, preferably 2% by mass or more, more preferably 3% by mass or more, and more preferably. Can be contained in an amount of 5% by mass or more, more preferably 10% by mass or more. There has never been a technique for uniformly dispersing such high-concentration hydroxyapatite in water. Further, it has been confirmed that the dispersion liquid of the present invention can contain 40% by mass or 45% by mass without any particular upper limit of hydroxyapatite. Preferably, hydroxyapatite can be contained in an amount of 20% by mass or less. The dispersion liquid of the present invention is one in which hydroxyapatite is stably dispersed, and precipitation is unlikely to occur even if it is allowed to stand. Whether or not precipitation is unlikely to occur can be quickly confirmed by centrifuging. For example, the dispersion of the present invention has substantially no precipitation of hydroxyapatite after centrifugation at 3600 rpm for 10 minutes at room temperature, and substantially no precipitation of hydroxyapatite after being allowed to stand at room temperature for 12 hours. Those that do not occur are preferable. Here, the fact that hydroxyapatite precipitates do not substantially occur means that a white precipitate cannot be clearly confirmed by visual inspection.
 ハイドロキシアパタイトを均一に分散させた分散液は、ハイドロキシアパタイトを任意の物、例えば不織布、フィルタ、ガーゼ、マスク、壁などに対して塗布によって付着させることができる。塗布法は、特に限定されないが例えばスプレーコート、ディッピング(どぶづけ)、ポッティング、ローラコート、スピンコート等を挙げることができる。これらの塗布法は、均一に塗布でき、また、簡便かつ大量生産に向いているので、ハイドロキシアパタイトを付着させた製品を、安価で大量に製造することができる。また、本発明のマスク、フィルタは、ハイドロキシアパタイトの粉落ちが少ないという効果が期待できる。 The dispersion liquid in which hydroxyapatite is uniformly dispersed can adhere hydroxyapatite to any object, for example, non-woven fabric, filter, gauze, mask, wall, etc. by application. The coating method is not particularly limited, and examples thereof include spray coating, dipping, potting, roller coating, spin coating and the like. Since these coating methods can be applied uniformly, are simple and suitable for mass production, products to which hydroxyapatite is attached can be mass-produced at low cost. In addition, the mask and filter of the present invention can be expected to have the effect of reducing the amount of hydroxyapatite powder falling off.
 ハイドロキシアパタイト粉末は、吸着性を有するので、例えばハイドロキシアパタイトの水分散液を不織布やマスクに塗布してこれらの対象物にハイドロキシアパタイトを付着させることにより、花粉、PM2.5、ウイルス等を吸着させることが期待できる。
 また、本発明の分散液によれば、ハイドロキシアパタイト粉末に限られず、炭素粉末、亜鉛粉末及び食材粉末から選ばれる少なくとも一種の粉末についても安定的に分散させることができる。
Since hydroxyapatite powder has adsorptive properties, for example, by applying an aqueous dispersion of hydroxyapatite to a non-woven fabric or a mask and adhering hydroxyapatite to these objects, pollen, PM2.5, viruses, etc. are adsorbed. Can be expected.
Further, according to the dispersion liquid of the present invention, not only hydroxyapatite powder but also at least one powder selected from carbon powder, zinc powder and food material powder can be stably dispersed.
 本発明の分散液の成分をより具体的に説明する。
(水不溶粉末)
 水不溶粉末は、水に溶解しない粉末をいい、本発明の技術で安定的に分散させることができる粉末は、ハイドロキシアパタイトや、炭素粉末、亜鉛粉末、食材粉末等が挙げられる。
(ハイドロキシアパタイト)
 ハイドロキシアパタイトは、市販のハイドロキシアパタイトを用いることができる。市販のハイドロキシアパタイトは、鉱物由来のものや生物由来のものがあるが、鉱物由来のものも生物由来のものも、いずれのハイドロキシアパタイトをも用いることができるが、生物由来のハイドロキシアパタイトが好ましい。生物由来のハイドロキシアパタイトとは、ハイドロキシアパタイトを得るためのカルシウム源として、生物の構成要素(骨、サンゴ、貝殻、卵殻等)を用いて得られるハイドロキシアパタイトのことである。ハイドロキシアパタイトは、例えば、酸化カルシウム溶液(懸濁液)または水酸化カルシウム溶液(懸濁液)にリン酸溶液を添加し、或いは、リン酸溶液に酸化カルシウム溶液(懸濁液)又は水酸化カルシウム溶液(懸濁液)を添加することにより得ることができる。そして、生物由来のハイドロキシアパタイトとは、例えば、骨、サンゴ、貝殻、卵殻等のカルシウム分を含む生体材料を焼成して、酸化カルシウムないし水酸化カルシウムを得て、これを水溶液又は懸濁液とし、リン酸溶液の添加によって得られるハイドロキシアパタイトである。また、生物由来のハイドロキシアパタイトの中には、X線構造解析において、2θが31.500~32.500°に現れるピークの結晶子サイズが10~200Å、好ましくは30~150Å、より好ましくは50~120Åのハイドロキシアパタイトであるものがある(以下、説明のために「特定ハイドロキシアパタイト」とも称する。)。結晶子サイズとは、結晶粒の大きさを表し、結晶性を表す目安となる数値である。結晶子サイズの数値が大きいほど、測定対象である物質の結晶性が高いことを意味する。結晶子サイズが前記範囲にあるハイドロキシアパタイトは、結晶化していない(非結晶型)ハイドロキシアパタイトのみ又は非結晶型ハイドロキシアパタイトと結晶化の程度が低い(低結晶型)ハイドロキシアパタイトとが混合されたものを意味する。ここで、本発明における「非結晶型ハイドロキシアパタイト」とは、X線解析によって、図3のようなチャートが得られる物質を意味する。また、本発明における「低結晶型ハイドロキシアパタイト」とは、X線解析によって得られるチャートが、結晶型ハイドロキシアパタイトのX線解析によって得られるチャート(例えば、図2のチャート参照)と比較してピークの分離の程度が比較的低い物質である。
 結晶子サイズは、例えば、株式会社リガク社製のX線解析装置 型番:RINT2200V/PCにより測定できる。
 なお、ハイドロキシアパタイトには、上述した特定ハイドロキシアパタイト以外のハイドロキシアパタイト等を含んでいてもよい。
The components of the dispersion liquid of the present invention will be described more specifically.
(Water-insoluble powder)
The water-insoluble powder refers to a powder that is insoluble in water, and examples of the powder that can be stably dispersed by the technique of the present invention include hydroxyapatite, carbon powder, zinc powder, and food powder.
(Hydroxyapatite)
As hydroxyapatite, commercially available hydroxyapatite can be used. Commercially available hydroxyapatite includes those derived from minerals and those derived from living organisms, and any hydroxyapatite derived from minerals or living organisms can be used, but hydroxyapatite derived from living organisms is preferable. Organism-derived hydroxyapatite is hydroxyapatite obtained by using biological components (bone, coral, shell, eggshell, etc.) as a calcium source for obtaining hydroxyapatite. For hydroxyapatite, for example, a phosphoric acid solution is added to a calcium oxide solution (suspension) or a calcium hydroxide solution (suspension), or a calcium oxide solution (suspension) or calcium hydroxide is added to the phosphoric acid solution. It can be obtained by adding a solution (suspension). Hydroxyapatite derived from living organisms is, for example, calcined biological materials containing calcium such as bones, coral, shells, and eggshells to obtain calcium oxide or calcium hydroxide, which is used as an aqueous solution or a suspension. , Hydroxyapatite obtained by the addition of a phosphoric acid solution. Further, in the hydroxyapatite derived from living organisms, the crystallite size of the peak in which 2θ appears at 31.500 to 32.500 ° in X-ray structural analysis is 10 to 200 Å, preferably 30 to 150 Å, more preferably 50. Some are hydroxyapatite up to 120 Å (hereinafter, also referred to as "specific hydroxyapatite" for the sake of explanation). The crystallinity size represents the size of crystal grains and is a numerical value that serves as a guide for expressing crystallinity. The larger the value of the crystallinity size, the higher the crystallinity of the substance to be measured. Hydroxyapatite having a crystallite size in the above range is only uncrystallized (amorphous) hydroxyapatite or a mixture of amorphous hydroxyapatite and low degree of crystallization (low crystal type) hydroxyapatite. Means. Here, the "amorphous hydroxyapatite" in the present invention means a substance for which a chart as shown in FIG. 3 can be obtained by X-ray analysis. Further, the "low crystalline hydroxyapatite" in the present invention means that the chart obtained by X-ray analysis has a peak as compared with the chart obtained by X-ray analysis of crystalline hydroxyapatite (see, for example, the chart in FIG. 2). It is a substance with a relatively low degree of separation.
The crystallite size can be measured by, for example, an X-ray analyzer model number: RINT2200V / PC manufactured by Rigaku Co., Ltd.
The hydroxyapatite may contain hydroxyapatite or the like other than the above-mentioned specific hydroxyapatite.
 卵殻由来のハイドロキシアパタイトには、株式会社バイオアパタイトの商品名バイオアパタイト(商標)がある。現時点で市場で入手可能な特定ハイドロキシアパタイトはバイオアパタイトのみであり、そのため市場で入手される特定ハイドロキシアパタイトは、卵殻由来のアパタイトと推定される。 Hydroxyapatite derived from eggshell has the trade name Bioapatite (trademark) of Bioapatite Co., Ltd. At present, the only specific hydroxyapatite available on the market is bioapatite, so the specific hydroxyapatite available on the market is presumed to be eggshell-derived apatite.
 本発明で使用するハイドロキシアパタイトは、平均粒子径は特に限定されないが、平均粒子径が1~30μmであることが好ましく、より好ましくは1~20μm、さらに好ましくは1~10μmである。平均粒子径は、レーザー光散乱回折法で測定することができる。
The average particle size of the hydroxyapatite used in the present invention is not particularly limited, but the average particle size is preferably 1 to 30 μm, more preferably 1 to 20 μm, and further preferably 1 to 10 μm. The average particle size can be measured by a laser light scattering diffraction method.
(セルロース誘導体)
 本発明のセルロース誘導体は、セルロース又はセルロースを置換ないし化学修飾した化合物又はその塩である。セルロースの置換度は特に限定されない。セルロース誘導体としては、例えば、セルロース、メチルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロースナトリウムが挙げられ、メチルセルロース若しくはその塩又はカルボキシメチルセルロース若しくはその塩(例えば、カルボキシメチルセルロースナトリウム)が好ましく、メチルセルロースがより好ましい。カルボキシメチルセルロースナトリウムは増粘剤等として市販のものを用いることができる。食品添加物グレードのものや、工業用グレードのものがあるが、分散液の用途に応じて、いずれも用いることができる。
(Cellulose derivative)
The cellulose derivative of the present invention is cellulose or a compound in which cellulose is substituted or chemically modified, or a salt thereof. The degree of substitution of cellulose is not particularly limited. Examples of the cellulose derivative include cellulose, methyl cellulose, carboxymethyl cellulose and sodium carboxymethyl cellulose, and methyl cellulose or a salt thereof or carboxymethyl cellulose or a salt thereof (for example, sodium carboxymethyl cellulose) is preferable, and methyl cellulose is more preferable. Commercially available sodium carboxymethyl cellulose can be used as a thickener or the like. There are food additive grade and industrial grade, but any of them can be used depending on the use of the dispersion.
 セルロース誘導体は、粉末の粒径は特に限定されず、市販されているセルロース誘導体をそのまま用いることができる。 As the cellulose derivative, the particle size of the powder is not particularly limited, and a commercially available cellulose derivative can be used as it is.
 メチルセルロースやカルボキシメチルセルロースナトリウムなどのセルロース誘導体の含有量は、水を含む分散液中に2質量%以下であり、好ましくは0.1~2質量%である。2質量%を超える含有量を水に溶解させるのが難しい。下限は特に限定されないが、含有量が少ないとハイドロキシアパタイト粉末を水に分散させる効果が低下する。 The content of the cellulose derivative such as methyl cellulose and sodium carboxymethyl cellulose is 2% by mass or less, preferably 0.1 to 2% by mass in the dispersion liquid containing water. It is difficult to dissolve a content of more than 2% by mass in water. The lower limit is not particularly limited, but if the content is low, the effect of dispersing the hydroxyapatite powder in water is reduced.
(極性溶媒)
 極性溶媒は、酸素(ヒドロキシ基)や窒素(アミン)等に結合した水素原子を含む溶媒であり、ハイドロキシアパタイトとセルロース誘導体とを含むペースト組成物を製造する際に使用する。また、ハイドロキシアパタイト分散液の溶媒としても用いることができる。極性溶媒としては、水、グリセリン、ポリエチレングリコール、グリセロール、アルコール(メタノール、エタノール、ブタノール、プロパノール)、ギ酸、酢酸又はこれらの混合物等が挙げられる。また、PBS、PBSTといったバッファーや、EDTA、DTT又はメルカプトエタノールといった成分を含む水溶液を極性溶媒として用いることもできる。
 ハイドロキシアパタイト分散液の溶媒と、ペースト組成物中の極性溶媒は同一である必要はない。ハイドロキシアパタイト分散液の溶媒としては、水が好ましい。ペースト組成物の極性溶媒としては、グリセリン、ポリエチレングリコールが好ましい。
 なお、本発明のペースト組成物に酵素を配合する場合、市販の酵素液をそのまま用いて、別途極性溶媒を加えないこともできる。これは、市販の酵素は、極性溶媒中に保存されており、この極性溶媒を用いることでペースト組成物を製造することができるためである。
(Polar solvent)
The polar solvent is a solvent containing a hydrogen atom bonded to oxygen (hydroxy group), nitrogen (amine) or the like, and is used when producing a paste composition containing hydroxyapatite and a cellulose derivative. It can also be used as a solvent for hydroxyapatite dispersion. Examples of the polar solvent include water, glycerin, polyethylene glycol, glycerol, alcohol (methanol, ethanol, butanol, propanol), formic acid, acetic acid or a mixture thereof. Further, a buffer such as PBS or PBST or an aqueous solution containing a component such as EDTA, DTT or mercaptoethanol can be used as the polar solvent.
The solvent of the hydroxyapatite dispersion and the polar solvent in the paste composition do not have to be the same. Water is preferable as the solvent for the hydroxyapatite dispersion. As the polar solvent of the paste composition, glycerin and polyethylene glycol are preferable.
When the enzyme is blended in the paste composition of the present invention, a commercially available enzyme solution may be used as it is, and a polar solvent may not be added separately. This is because a commercially available enzyme is stored in a polar solvent, and a paste composition can be produced by using this polar solvent.
 ペースト組成物中、極性溶媒の好ましい配合割合は、ハイドロキシアパタイト10gに対して有機液100~200gである。 The preferable mixing ratio of the polar solvent in the paste composition is 100 to 200 g of the organic liquid with respect to 10 g of hydroxyapatite.
(その他の成分)
 本発明の分散液は、ハイドロキシアパタイト、セルロース誘導体の他に、抗菌成分等の機能的成分を含むことができる。例えば抗菌成分を含むことにより、マスクや不織布に分散液を付着させたときに抗菌成分の作用により抗菌効果を奏することができる。本発明のハイドロキシアパタイト分散液が抗菌成分を含有する場合、消毒用アルコールと同等以上の効果が期待できる。これは、消毒用アルコールは揮発性であるため、消毒の効果は一時的なものであるが、本発明の分散液は持続性のある抗菌効果が期待できるからである。
(Other ingredients)
The dispersion of the present invention can contain functional components such as antibacterial components in addition to hydroxyapatite and cellulose derivatives. For example, by containing an antibacterial component, an antibacterial effect can be exerted by the action of the antibacterial component when the dispersion liquid is attached to a mask or a non-woven fabric. When the hydroxyapatite dispersion of the present invention contains an antibacterial component, it can be expected to have an effect equal to or higher than that of rubbing alcohol. This is because the disinfecting alcohol is volatile, so that the disinfecting effect is temporary, but the dispersion of the present invention can be expected to have a long-lasting antibacterial effect.
 抗菌成分としては、銅、銀、市販の歯磨き剤に含まれる塩化セチルピリジニウム(CPC)、イソプロピルメチルフェノール (IPMP)、ラウロイルサルコシンナトリウム(LSS)、塩酸クロルヘキシジン(CHX)や、トリクロサン(TC)等がある。これらの抗菌成分は、本発明の分散液に加えても抗菌活性が低下しない。 Examples of antibacterial components include copper, silver, cetylpyridinium chloride (CPC), isopropylmethylphenol (IPMP), lauroylsarcosine sodium (LSS), chlorhexidine hydrochloride (CHX), triclosan (TC), etc. contained in commercially available dentifrices. be. These antibacterial components do not reduce their antibacterial activity even when added to the dispersion of the present invention.
(製造方法)
 本発明の分散液の製造方法の一例をハイドロキシアパタイト粉末の例で説明する。
 ハイドロキシアパタイト粉末、セルロース誘導体粉末、極性溶媒を混ぜ合わせてペースト組成物を得る。製造時の温度は常温でよく、加熱や冷却をする必要はない。
(Production method)
An example of the method for producing the dispersion liquid of the present invention will be described with the example of hydroxyapatite powder.
Hydroxyapatite powder, cellulose derivative powder, and polar solvent are mixed to obtain a paste composition. The manufacturing temperature may be normal temperature, and there is no need to heat or cool it.
 得られたペースト組成物に、水などの極性溶媒を加えてハイドロキシアパタイト粉末が所定濃度の水分散液を得る。この場合、ペースト組成物を得る際に用いた極性溶媒と同じ極性溶媒を用いる必要はない。水は高純度水、例えば逆浸透膜水を用いることができるが、用途に応じて水道水を用いることもできる。 A polar solvent such as water is added to the obtained paste composition to obtain an aqueous dispersion having a predetermined concentration of hydroxyapatite powder. In this case, it is not necessary to use the same polar solvent as the polar solvent used to obtain the paste composition. As the water, high-purity water, for example, reverse osmosis membrane water can be used, but tap water can also be used depending on the application.
 抗菌成分を加えるときは、ハイドロキシアパタイト粉末が所定濃度の水分散液に抗菌成分を加えてもよいし、それ以前の工程時に加えてもよい。
 本発明の製造方法によれば高濃度のハイドロキシアパタイトを含む分散液を、高効率、低コストで製造することができる。
When the antibacterial component is added, the hydroxyapatite powder may be added to the aqueous dispersion having a predetermined concentration, or the antibacterial component may be added at the time of the previous step.
According to the production method of the present invention, a dispersion containing a high concentration of hydroxyapatite can be produced with high efficiency and low cost.
(用途)
 本発明の分散液は、不織布、ガーゼ、マスク、フィルタ、壁などに塗布することができる。塗布方法は、特に限定されないが例えばスプレーコート、ディッピング(どぶづけ)、ポッティング、ローラコート、スピンコート等を挙げることができる。分散液が塗布された不織布、ガーゼ等を加工してマスクにすることができ、また、エアコン等のフィルタに用いることができる。例えばマスクの用途において、ハイドロキシアパタイトの吸着効果により花粉、PM2.5、ウイルス等の吸着が期待できる。また、エアコン等のフィルタの用途においては、花粉、PM2.5、ウイルス等の吸着の他、消臭機能も期待できる。
 さらに、本発明の分散液が抗菌成分を含むときは、抗菌効果も期待できる。
(Use)
The dispersion liquid of the present invention can be applied to non-woven fabrics, gauze, masks, filters, walls and the like. The coating method is not particularly limited, and examples thereof include spray coating, dipping, potting, roller coating, spin coating and the like. Nonwoven fabric, gauze, etc. coated with a dispersion liquid can be processed into a mask, and can also be used as a filter for an air conditioner or the like. For example, in the use of masks, the adsorption effect of hydroxyapatite can be expected to adsorb pollen, PM2.5, viruses and the like. In addition to adsorbing pollen, PM2.5, viruses, etc., it can also be expected to have a deodorizing function in the use of filters such as air conditioners.
Further, when the dispersion liquid of the present invention contains an antibacterial component, an antibacterial effect can be expected.
 本発明の分散液の用途は、上述したマスクやフィルタに限られず、空気清浄等の幅広い用途に適用することができ、産業上の利用可能性は大きい。 The application of the dispersion liquid of the present invention is not limited to the above-mentioned masks and filters, but can be applied to a wide range of applications such as air purification, and has great industrial applicability.
 以下、実施例により本開示の内容をさらに詳しく説明する。実施例により、本開示の範囲が限定されないことは言うまでもない。 Hereinafter, the contents of the present disclosure will be described in more detail by way of examples. It goes without saying that the scope of the present disclosure is not limited by the examples.
 ハイドロキシアパタイトとして市販のハイドロキシアパタイト(和光純薬社製の商品名:ヒドロキシアパタイト)と、上述した特定ハイドロキシアパタイトとして卵殻由来のハイドロキシアパタイトであるバイオアパタイト社の商品名バイオアパタイト(以下、「エッグアパタイト」という。)を用意した。また、和光純薬社のカルボキシメチルセルロースナトリウムを用意した。さらに、極性溶媒としてグリセリンを用意した。 Hydroxyapatite (trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.) commercially available as hydroxyapatite, and bioapatite (hereinafter, "egguapatite"), which is a hydroxyapatite derived from eggshell as the specific hydroxyapatite described above. I prepared.). In addition, sodium carboxymethyl cellulose of Wako Pure Chemical Industries, Ltd. was prepared. Furthermore, glycerin was prepared as a polar solvent.
 ハイドロキシアパタイト10gと、カルボキシメチルセルロースナトリウム0.1gを混合した。この混合物をグリセリン10gに加えてかき混ぜ、ペースト組成物を得た。
 得られたペースト組成物に水50cmを加えて攪拌し、水分散液を得た(以下、ハイドロキシアパタイト分散液を「実施例」という。)。
10 g of hydroxyapatite and 0.1 g of sodium carboxymethyl cellulose were mixed. This mixture was added to 10 g of glycerin and stirred to obtain a paste composition.
50 cm 3 of water was added to the obtained paste composition and stirred to obtain an aqueous dispersion (hereinafter, the hydroxyapatite dispersion is referred to as "Example").
 得られた実施例のハイドロキシアパタイト水分散液について、室温で24時間静置したところ、いずれもハイドロキシアパタイトの沈殿は生じなかった。写真を図4及び図5に示す。図4及び図5の右側が実施例かつハイドロキシアパタイトが卵殻由来のハイドロキシアパタイト、すなわちバイオアパタイト社の商品名バイオアパタイトの例であり、図4及び図5の左側が比較例である。また、図4が分散液調製直後の写真であり、図5がそれを室温で静置した後の写真である。図4及び図5から明らかなように、静置後も実施例では沈殿が生じておらず、安定して分散した状態が保たれている。また3600rpm、10分間の遠心分離機にかけた後に観察したところ、いずれもハイドロキシアパタイトの沈殿は生じなかった。写真を図6及び図7に示す。図6が遠心分離前、図7が遠心分離後の写真である。また、図6及び図7の右側が実施例である。図6及び図7から明らかなように、遠心分離後も実施例では実質的に沈殿が生じていない。図4及び図5には表示していないが、ハイドロキシアパタイトが市販のハイドロキシアパタイト、すなわち和光純薬社製の商品名:ヒドロキシアパタイトである実施例についても、分散液調製直後及び室温で静置した後に沈殿が生じておらず、安定して分散した状態が保たれていた。また3600rpm、10分間の遠心分離機にかけた後に観察したところ、ハイドロキシアパタイトの沈殿は生じなかった。 When the obtained hydroxyapatite aqueous dispersion of the example was allowed to stand at room temperature for 24 hours, no precipitation of hydroxyapatite occurred. The photographs are shown in FIGS. 4 and 5. The right side of FIGS. 4 and 5 is an example, and hydroxyapatite is an example of hydroxyapatite derived from eggshell, that is, the trade name bioapatite of Bioapatite Co., Ltd., and the left side of FIGS. 4 and 5 is a comparative example. Further, FIG. 4 is a photograph immediately after preparing the dispersion, and FIG. 5 is a photograph after allowing it to stand at room temperature. As is clear from FIGS. 4 and 5, precipitation did not occur in the examples even after standing, and a stable and dispersed state was maintained. Further, when observed after centrifuging at 3600 rpm for 10 minutes, no precipitation of hydroxyapatite occurred. The photographs are shown in FIGS. 6 and 7. FIG. 6 is a photograph before centrifugation and FIG. 7 is a photograph after centrifugation. Further, the right side of FIGS. 6 and 7 is an example. As is clear from FIGS. 6 and 7, no precipitation is substantially formed in the examples even after centrifugation. Although not shown in FIGS. 4 and 5, examples in which hydroxyapatite is commercially available hydroxyapatite, that is, trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd., were also allowed to stand immediately after preparation of the dispersion and at room temperature. No precipitation occurred later, and a stable and dispersed state was maintained. Further, when observed after centrifuging at 3600 rpm for 10 minutes, no precipitation of hydroxyapatite occurred.
 また、得られたヒドロキシアパタイト水分散液及びエッグアパタイト水分散液に、それぞれ抗菌成分として塩化セチルピリジニウム(CPC)を添加したものについて、それぞれ10日間放置したところ、いずれもハイドロキシアパタイトの沈殿は生じなかった。また3600rpmの遠心分離機にかけた後に観察したところ、いずれもハイドロキシアパタイトの沈殿は生じなかった。 Further, when the obtained hydroxyapatite aqueous dispersion and egguapatite aqueous dispersion to which cetylpyridinium chloride (CPC) was added as an antibacterial component were left for 10 days, hydroxyapatite precipitation did not occur in any of them. rice field. Further, when observed after being subjected to a centrifuge at 3600 rpm, no precipitation of hydroxyapatite occurred.
 比較例として、ヒドロキシアパタイト10gに水50cmを加えて攪拌したところ、攪拌終了後しばらくして、ヒドロキシアパタイトが沈殿した。写真を図4及び図5に示す。図4及び図5の左側が比較例である。図4及び図5から明らかなように、比較例では沈殿が生じている。また、比較例を遠心分離機にかけた際の写真を図6及び図7に示す。図6及び図7の左側が実施例である。図6及び図7から明らかなように、遠心分離機にかけた後に比較例では沈殿が生じている。
 また、エッグアパタイト10gに水50cmを加えて攪拌したところ、攪拌終了後すぐに、ハイドロキシアパタイトが沈殿した。
As a comparative example, when 50 cm 3 of water was added to 10 g of hydroxyapatite and stirred, hydroxyapatite was precipitated shortly after the completion of stirring. The photographs are shown in FIGS. 4 and 5. The left side of FIGS. 4 and 5 is a comparative example. As is clear from FIGS. 4 and 5, precipitation occurs in the comparative example. Further, photographs of a comparative example when subjected to a centrifuge are shown in FIGS. 6 and 7. The left side of FIGS. 6 and 7 is an example. As is clear from FIGS. 6 and 7, precipitation occurs in the comparative example after being centrifuged.
Further, when 50 cm 3 of water was added to 10 g of egguapatite and stirred, hydroxyapatite was precipitated immediately after the stirring was completed.
 ハイドロキシアパタイトとして市販のハイドロキシアパタイト(和光純薬社製の商品名:ヒドロキシアパタイト)を用意した。また、市販のメチルセルロース(信越セルロース社製の商品名メトローズ)を用意した。さらに、極性溶媒としてグリセリンを用意した。 A commercially available hydroxyapatite (trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.) was prepared as hydroxyapatite. In addition, commercially available methyl cellulose (trade name Metrose manufactured by Shinetsu Cellulose Co., Ltd.) was prepared. Furthermore, glycerin was prepared as a polar solvent.
 上記のハイドロキシアパタイト10gと、上記のメチルセルロース0.1gを混合した。この混合物をグリセリン10gに加えてかき混ぜ、ペースト組成物を得た。
 得られたペースト組成物に水50cmを加えて攪拌し、水分散液を得た。
10 g of the above hydroxyapatite and 0.1 g of the above methylcellulose were mixed. This mixture was added to 10 g of glycerin and stirred to obtain a paste composition.
50 cm 3 of water was added to the obtained paste composition and stirred to obtain an aqueous dispersion.
 得られたハイドロキシアパタイト水分散液について、室温で24時間静置したところ、ハイドロキシアパタイトの沈殿は生じなかった。また3600rpm、10分間の遠心分離機にかけた後に観察したところ、ハイドロキシアパタイトの沈殿は生じなかった。遠心分離機にかけた後の分散液の写真を図8に示す。図8から明らかなように、遠心分離機にかけた後も実質的に沈殿が生じていなかった。 When the obtained hydroxyapatite aqueous dispersion was allowed to stand at room temperature for 24 hours, no precipitation of hydroxyapatite occurred. Further, when observed after centrifuging at 3600 rpm for 10 minutes, no precipitation of hydroxyapatite occurred. A photograph of the dispersion liquid after being centrifuged is shown in FIG. As is clear from FIG. 8, no precipitation was substantially formed even after the centrifugation.
 また、得られたヒドロキシアパタイト水分散液抗菌成分として塩化セチルピリジニウム(CPC)を添加したものについて、それぞれ10日間放置したところ、ハイドロキシアパタイトの沈殿は生じなかった。また3600rpmの遠心分離機にかけた後に観察したところ、ハイドロキシアパタイトの沈殿は生じなかった。 Further, when the obtained hydroxyapatite aqueous dispersion to which cetylpyridinium chloride (CPC) was added as an antibacterial component was left for 10 days, no precipitation of hydroxyapatite occurred. Further, when observed after centrifuging at 3600 rpm, no precipitation of hydroxyapatite occurred.
 ハイドロキシアパタイトとして市販のハイドロキシアパタイト(和光純薬社製の商品名:ヒドロキシアパタイト)を用意した。また、市販のメチルセルロース(信越セルロース社製の商品名メトローズ)を用意した。 A commercially available hydroxyapatite (trade name: hydroxyapatite manufactured by Wako Pure Chemical Industries, Ltd.) was prepared as hydroxyapatite. In addition, commercially available methyl cellulose (trade name Metrose manufactured by Shinetsu Cellulose Co., Ltd.) was prepared.
 上記のハイドロキシアパタイト40gと、上記のメチルセルロース2.0gを混合した。次いでグリセリン10gを加えてかき混ぜ、ペースト組成物を得た。さらに水50cmを加えて攪拌し、水分散液を得た。
 また、別の例として上記のハイドロキシアパタイト45gと、上記のメチルセルロース2.0gを混合した。次いでグリセリン10gを加えてかき混ぜ、ペースト組成物を得た。さらに水45cmを加えて攪拌し、水分散液を得た。
40 g of the above hydroxyapatite and 2.0 g of the above methylcellulose were mixed. Then, 10 g of glycerin was added and stirred to obtain a paste composition. Further, 50 cm 3 of water was added and stirred to obtain an aqueous dispersion.
As another example, 45 g of the above hydroxyapatite and 2.0 g of the above methylcellulose were mixed. Then, 10 g of glycerin was added and stirred to obtain a paste composition. Further, 45 cm 3 of water was added and stirred to obtain an aqueous dispersion.
 得られた各ハイドロキシアパタイト水分散液について、室温で24時間静置したところ、ハイドロキシアパタイトの沈殿は生じなかった。また3600rpm、10分間の遠心分離機にかけた後に観察したところ、ハイドロキシアパタイトの沈殿は生じなかった。     When each of the obtained hydroxyapatite aqueous dispersions was allowed to stand at room temperature for 24 hours, no precipitation of hydroxyapatite occurred. Further, when observed after centrifuging at 3600 rpm for 10 minutes, no precipitation of hydroxyapatite occurred. Twice
 比較例として、マスク用塗布剤として市販されているハイドロキシアパタイト含有液を調べたところ、ハイドロキシアパタイトとエタノールと水と精油とを含む組成であり、液中にハイドロキシアパタイトが沈殿しているものであった。このマスク用塗布剤は使用の都度にハイドロキシアパタイト含有液が収容されている容器をよく振る使い方であり、マスクへの塗布前に振るという煩わしい作業を要し、また振り方が十分でないとマスクに塗布剤を均一に塗布できなかった。 As a comparative example, when a commercially available hydroxyapatite-containing liquid as a coating agent for masks was examined, it was found that the composition contained hydroxyapatite, ethanol, water, and essential oil, and hydroxyapatite was precipitated in the liquid. rice field. This mask coating agent is used to shake the container containing the hydroxyapatite-containing liquid each time it is used, which requires the troublesome work of shaking before applying to the mask, and if the shaking method is not sufficient, the mask will be used. The coating agent could not be applied evenly.

Claims (12)

  1.  セルロース誘導体を含むことを特徴とする水不溶粉末の分散液。 A dispersion of water-insoluble powder characterized by containing a cellulose derivative.
  2.  前記水不溶粉末がハイドロキシアパタイトである請求項1記載の分散液。 The dispersion liquid according to claim 1, wherein the water-insoluble powder is hydroxyapatite.
  3.  3600rpmで10分間遠心したときに、水不溶粉末の沈殿が実質的に生じない請求項2記載の分散液。 The dispersion liquid according to claim 2, wherein the water-insoluble powder does not substantially precipitate when centrifuged at 3600 rpm for 10 minutes.
  4.  前記セルロース誘導体が、メチルセルロース若しくはその塩又はカルボキシメチルセルロース若しくはその塩である請求項1~3のいずれか一項記載の分散液。 The dispersion liquid according to any one of claims 1 to 3, wherein the cellulose derivative is methyl cellulose or a salt thereof or carboxymethyl cellulose or a salt thereof.
  5.  溶媒が水である請求項1~4のいずれか一項記載の分散液。 The dispersion liquid according to any one of claims 1 to 4, wherein the solvent is water.
  6.  水不溶粉末を0.1質量%以上含有する請求項1~5のいずれか一項記載の分散液。 The dispersion liquid according to any one of claims 1 to 5, which contains 0.1% by mass or more of water-insoluble powder.
  7.  さらに、酵素を含有する請求項1~6のいずれか一項記載の分散液。 Further, the dispersion liquid according to any one of claims 1 to 6, which contains an enzyme.
  8.  さらに、抗菌剤を含有する請求項1~7のいずれか一項記載の分散液。 Further, the dispersion liquid according to any one of claims 1 to 7, which contains an antibacterial agent.
  9.  水不溶粉末、セルロース誘導体及び極性溶媒を含むペースト組成物。 A paste composition containing a water-insoluble powder, a cellulose derivative and a polar solvent.
  10.  水不溶粉末、セルロース誘導体及び極性溶媒を混合してペースト組成物を製造する工程、及び前記ペースト組成物を極性溶媒に分散させる工程を含むことを特徴とする水不溶粉末の分散液の製造方法。 A method for producing a dispersion liquid of a water-insoluble powder, which comprises a step of mixing a water-insoluble powder, a cellulose derivative and a polar solvent to produce a paste composition, and a step of dispersing the paste composition in a polar solvent.
  11.  ハイドロキシアパタイト及びセルロース誘導体を担持することを特徴とするフィルタ。 A filter characterized by supporting hydroxyapatite and a cellulose derivative.
  12.  ハイドロキシアパタイト及びセルロース誘導体を担持することを特徴とするマスク。 A mask characterized by carrying hydroxyapatite and a cellulose derivative.
PCT/JP2021/020706 2020-06-01 2021-05-31 Dispersion WO2021246373A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022528826A JPWO2021246373A1 (en) 2020-06-01 2021-05-31

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-095705 2020-06-01
JP2020095705 2020-06-01

Publications (1)

Publication Number Publication Date
WO2021246373A1 true WO2021246373A1 (en) 2021-12-09

Family

ID=78830310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/020706 WO2021246373A1 (en) 2020-06-01 2021-05-31 Dispersion

Country Status (3)

Country Link
JP (1) JPWO2021246373A1 (en)
TW (1) TW202210411A (en)
WO (1) WO2021246373A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05222693A (en) * 1991-10-28 1993-08-31 Asahi Optical Co Ltd Production of functional nonwoven fabric
JPH06170131A (en) * 1992-12-01 1994-06-21 Sumiaki Tsuru Filter material and manufacture thereof
JPH11217321A (en) * 1998-01-30 1999-08-10 Sanpo Seiyaku Kk Dentifrice composition
JP2001299280A (en) * 2000-04-20 2001-10-30 Mitsui Chemicals Inc Calcium supplement including polysaccharide having carboxyl group and calcium-enriched agent
JP2004026963A (en) * 2002-06-25 2004-01-29 Mitsui Chemicals Inc Aqueous solution of dispersed polymer compound / plate-like hydroxyapatite composite with excellent dispersion stability and its preparation process, and application
JP2007001865A (en) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same
JP2008056889A (en) * 2006-08-01 2008-03-13 Nippon Paper Chemicals Co Ltd Amorphous cellulose derivative
JP2014028935A (en) * 2012-06-26 2014-02-13 Toray Ind Inc Method for producing carboxymethylcellulose, dispersant of carboxymethylcellulose and carbone nanotube-containing composition
WO2016199927A1 (en) * 2015-06-12 2016-12-15 日産化学工業株式会社 Calcium salt composition and filaggrin production promoter using same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05222693A (en) * 1991-10-28 1993-08-31 Asahi Optical Co Ltd Production of functional nonwoven fabric
JPH06170131A (en) * 1992-12-01 1994-06-21 Sumiaki Tsuru Filter material and manufacture thereof
JPH11217321A (en) * 1998-01-30 1999-08-10 Sanpo Seiyaku Kk Dentifrice composition
JP2001299280A (en) * 2000-04-20 2001-10-30 Mitsui Chemicals Inc Calcium supplement including polysaccharide having carboxyl group and calcium-enriched agent
JP2004026963A (en) * 2002-06-25 2004-01-29 Mitsui Chemicals Inc Aqueous solution of dispersed polymer compound / plate-like hydroxyapatite composite with excellent dispersion stability and its preparation process, and application
JP2007001865A (en) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same
JP2008056889A (en) * 2006-08-01 2008-03-13 Nippon Paper Chemicals Co Ltd Amorphous cellulose derivative
JP2014028935A (en) * 2012-06-26 2014-02-13 Toray Ind Inc Method for producing carboxymethylcellulose, dispersant of carboxymethylcellulose and carbone nanotube-containing composition
WO2016199927A1 (en) * 2015-06-12 2016-12-15 日産化学工業株式会社 Calcium salt composition and filaggrin production promoter using same

Also Published As

Publication number Publication date
JPWO2021246373A1 (en) 2021-12-09
TW202210411A (en) 2022-03-16

Similar Documents

Publication Publication Date Title
Wilson Jr et al. Surface modification of nanophase hydroxyapatite with chitosan
Tank et al. Pure and zinc doped nano-hydroxyapatite: Synthesis, characterization, antimicrobial and hemolytic studies
CN101677530B (en) Antimicrobial material
CN103785857B (en) A kind of Nano Silver for antiseptic dressing and preparation method
JP2011528746A (en) Three-dimensional nanocomposite consisting of polysaccharide matrix and metal nanoparticles, and preparation and use thereof
AU2013330999A1 (en) Stable peracid-containing compositions
US20210038760A1 (en) Biomimetic bone composite material, a preparation method and uses thereof
CN106146862A (en) A kind of supermolecule heterozygosis hydrogel of antibiotic property and its preparation method and application
JP3846369B2 (en) Pasty deodorant and deodorant product produced using the deodorant
CN111034720A (en) Preparation method of zinc oxide-metal organic framework composite antibacterial material
WO2021246373A1 (en) Dispersion
KR101318348B1 (en) Method for Preparing Hydroxyapatite from Vaterite Containing Catecholamine
JP2019178219A (en) Composite particle, method for producing composite particle and antibacterial agent
KR20120112968A (en) Method for preparing polyurethane film comprising apatite with high antibacterial function
JP4203302B2 (en) Antibacterial coating liquid, method for producing the same, and coating method
Anwar et al. Novel synthesis and antimicrobial studies of nanoscale titania particles
JP7315943B2 (en) Porous support containing hydroxyapatite
JP2018076223A (en) Strontium apatite silicate, and cell culture substrate and bioactive implant containing the same
CN106752221A (en) A kind of aqueous drawing pigment and preparation method thereof
JP2007191453A (en) Noncrystalline calcium citrate-calcium carbonate composite and method for producing the same
CN103651569A (en) Technology for preparing surface-coated modified Ag/ZnO nano composite antibacterial agent
US8178066B2 (en) Method for stabilizing calcium phosphates fine particles, method for manufacturing calcium phosphates fine particles by using the method, and use thereof
CN113455517A (en) Environment-friendly slow-release antibacterial disinfection emulsion and preparation method thereof
Wijesinghe et al. Colloidal hydroxyapatite/poly (acrylic acid) hybrids using calcium sucrate and ammoniumdihydrogen orthophosphate
Wang et al. Synthesis of silver modified hydroxyapatite nanoparticle and evaluation of its biological properties in vitro for potential biomedical application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21817328

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022528826

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21817328

Country of ref document: EP

Kind code of ref document: A1